Antifibrotic agent 1
Antifibrotic agent 1 is an orally active anti-idiopathic pulmonary fibrosis (IPF) agent. Antifibrotic agent 1 effectively attenuates IPF-related processes, including TGF-β induced EMT and FMT processes, as well as pro-fibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α and Src family kinases (SFKs), while sparing VEGFRs, FGFRs and Abl to minimize off-target toxicity. Antifibrotic agent 1 has potent anti-fibrotic activity in Bleomycin (BLM) (HY-108345)-induced pulmonary fibrosis mice model.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C27H23ClN6O2
- Masse moléculaire:498.96
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
PDGFRα |
Collagen I 40.5 nM (IC50) |
Fyn |
Hck |
Lyn |
Lck |
Yes |
Antifibrotic agent 1 (Compound 22) (0.001-10 μM, 48 h,) exhibits profound anti-fibrotic activity, suppressing COL1A1 expression by 95.0% at 1 μM, with an IC50 of 40.5 nM in A549 cells[1].
Antifibrotic agent 1 (1-200 μM) exhibits anti-fibrotic effects with low cytotoxicity across A549, HEK293 and L02 cells (CC50 > 200μM)[1].
Antifibrotic agent 1 (0.1-10 μM, 48 h) dose-dependently reduces the protein level of COL1A1, inhibiting IPF-related EMT and FMT processes in TGF-β-stimulated A549, HFL1 and HLFs cells[1].
Antifibrotic agent 1 (1-10 μM, 48 h) selectively inhibits the bone marrow-derived macrophages (BMDM) polarization towards the pro-fibrotic M2 phenotype at a concentration of 10 μM[1].
Antifibrotic agent 1 (1-100 nM) selectively inhibits CSF-1R, PDGFR-α and SFKs to mitigate IPF progression, while sparing VEGFRs, FGFRs and Abl to minimize off-target toxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A549 cells, HFL1 cells, HLFs cells
-
Concentration:0.1, 0.5, 1, 10 μM
-
Incubation Time:48 h after TGF-β stimulated 48 h
-
Result:Dose-dependently reduced the protein level of COL1A1 in IPF-related EMT and FMT models and primary human lung fibroblasts model.
| Species | Dose | Route | T1/2 | AUC | MRT | Clearance (CL) | Vd | Tmax | Plasma Concentration | Bioavailability |
|---|---|---|---|---|---|---|---|---|---|---|
| Mice | 2 mg/kg | i.v. | 2.37 h | 437 ng·h/mL | 0.4 h | 79.8 mL/min/kg | 1.802 L/kg | / | / | / |
| Mice | 5 mg/kg | p.o. | 3.15 h | / | 2.32 h | / | / | 0.42 h | 137 ng·h/mL | 12.6 % |
Antifibrotic agent 1 (60 mg/kg, p.o., daily for 10 days) has superior anti-fibrotic efficacy, significantly alleviating lung fibrosis, reducing inflammation and pro-fibrotic M2-associated cytokine levels, and improving lung function in BLM-induced pulmonary fibrosis mice model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male C57BL/6 mice (8 weeks old) were given an intratracheal administration of BLM (1.8 mg/kg) to induce pulmonary fibrosis[1].
-
Dosage:30, 60 mg/kg
-
Administration:Oral gavage (p.o.), daily for 14 days and then measured body and lung tissues weight as well as collected lung tissues.
-
Result:Significantly alleviated weight losses, increased survival rate and improved lung functions with increased lung coefficient value in mice mode.
Notably downregulated Tgf-β mRNA, reduced both the mRNA and protein levels of Fn1 and Col1a1, and decreased hydroxyproline content in the lung tissues in mice model at the dose of 60 mg/kg.
Significantly reduced Tnf and Ccl2 mRNA levels but increased IL-10 mRNA level, modulating inflammation to further alleviate pulmonary fibrosis in mice model.
Strongly downregulated M2-associated genes (Arg1, Mrc1) but not the M1 marker CD86, selectively inhibiting M2 macrophage polarization without significantly affecting M1 polarization in mice model.
Potently alleviated pathological changes related lung fibrosis and decreased collagen fibers with a 54.6 % reduction in fibrosis area in mice model at the dose of 60 mg/kg.
Chemical Information
-
Masse moléculaire 498.96
-
Formule C27H23ClN6O2
-
SMILES
CC(NC1=CC=C(C(Cl)=C1)NC(C2=CC=C(C(C#CC3=CC(C4=CN(N=C4)C)=CN=C3N)=C2)C)=O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Antifibrotic agent 1 Related Classifications
HY-176194 Related Classifications
Powered by Bioz